(Q41566153)

3 October 2017

1 reference

title

Plasma and tissue concentrations of fluconazole and their correlation to breakpoints (English)

1 reference

3 October 2017

1 reference

Pittrow L

1

1 reference

3 October 2017

Penk A

series ordinal

2

1 reference

3 October 2017

publication date

1 January 1997

1 reference

3 October 2017

1 reference

3 October 2017

volume

40

1 reference

3 October 2017

issue

1-2

1 reference

3 October 2017

page(s)

25-32

1 reference

Role of pharmacokinetics in the outcome of infections

3 October 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1439-0507.1997.TB00167.X

Antifungal susceptibility testing of isolates from a randomized, multicenter trial of fluconazole versus amphotericin B as treatment of nonneutropenic patients with candidemia. NIAID Mycoses Study Group and the Candidemia Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1439-0507.1997.TB00167.X

Comparison of relative susceptibilities of Candida species to three antifungal agents as determined by unstandardized methods

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1439-0507.1997.TB00167.X

Comparison of Etest and National Committee for Clinical Laboratory Standards broth macrodilution method for antifungal susceptibility testing: enhanced ability to detect amphotericin B-resistant Candida isolates

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1439-0507.1997.TB00167.X

Development of interpretive breakpoints for antifungal susceptibility testing: conceptual framework and analysis of in vitro-in vivo correlation data for fluconazole, itraconazole, and candida infections. Subcommittee on Antifungal Susceptibility Te

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1439-0507.1997.TB00167.X

Safety, plasma concentrations, and efficacy of high-dose fluconazole in invasive mold infections.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1439-0507.1997.TB00167.X

Pharmacokinetic evaluation of UK-49,858, a metabolically stable triazole antifungal drug, in animals and humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1439-0507.1997.TB00167.X

Pharmacokinetics of 18F-labeled fluconazole in healthy human subjects by positron emission tomography

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1439-0507.1997.TB00167.X

Pharmacokinetics of fluconazole in cerebrospinal fluid and serum in human coccidioidal meningitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1439-0507.1997.TB00167.X

Sputum levels of fluconazole in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1439-0507.1997.TB00167.X

Use of high-dose fluconazole as salvage therapy for cryptococcal meningitis in patients with AIDS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1439-0507.1997.TB00167.X

10.1111/J.1439-0507.1997.TB00167.X

21 January 2018

Identifiers

DOI

1 reference

3 October 2017

1 reference